To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Cerberus lines up €500m Bayer unit
Cerberus Capital Management, the US turnaround specialist, is reported to be in exclusive talks to buy German drug giant Bayer’s blood products unit for over €500 million.
